Qiagen NV (QGEN) Receives Average Rating of “Hold” from Analysts

Shares of Qiagen NV (NASDAQ:QGEN) have been given a consensus recommendation of “Hold” by the fifteen analysts that are covering the company, MarketBeat reports. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $37.40.

A number of brokerages have recently weighed in on QGEN. BidaskClub raised shares of Qiagen from a “sell” rating to a “hold” rating in a research note on Wednesday, August 29th. Commerzbank reissued a “buy” rating on shares of Qiagen in a research note on Wednesday, August 29th. Barclays reissued a “buy” rating and set a $43.00 price objective on shares of Qiagen in a research note on Thursday, September 6th. Zacks Investment Research raised shares of Qiagen from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. Finally, Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research note on Friday, August 3rd.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Parallel Advisors LLC boosted its position in Qiagen by 548.5% during the third quarter. Parallel Advisors LLC now owns 3,210 shares of the company’s stock worth $122,000 after acquiring an additional 2,715 shares during the last quarter. First Bank & Trust boosted its position in Qiagen by 156.0% during the second quarter. First Bank & Trust now owns 4,928 shares of the company’s stock worth $178,000 after acquiring an additional 3,003 shares during the last quarter. Prudential Financial Inc. acquired a new stake in Qiagen during the third quarter worth approximately $206,000. Private Trust Co. NA acquired a new stake in Qiagen during the third quarter worth approximately $233,000. Finally, Lourd Capital LLC acquired a new stake in Qiagen during the third quarter worth approximately $250,000. Hedge funds and other institutional investors own 62.23% of the company’s stock.

Shares of QGEN opened at $35.97 on Friday. Qiagen has a 1-year low of $30.44 and a 1-year high of $39.45.

Qiagen (NASDAQ:QGEN) last issued its quarterly earnings data on Monday, October 29th. The company reported $0.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.33 by $0.02. The business had revenue of $377.90 million for the quarter, compared to analysts’ expectations of $380.11 million. During the same period last year, the business earned $0.32 earnings per share. The company’s revenue for the quarter was up 3.8% on a year-over-year basis.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Read More: What is a stock buyback?

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply